10-K: Cardiff Oncology Files 10-K Annual Report, Provides Update on Clinical Programs

Cardiff Oncology's 10-K filing details the company's financial status, clinical trial progress, and future plans, highlighting its focus on onvansertib development.

Summary

• Cardiff Oncology, a clinical-stage biotech company, released its 10-K annual report, outlining its financial performance and clinical development activities.
• The company is focused on developing onvansertib, a PLK1 inhibitor, for various cancers, particularly RAS-mutated metastatic colorectal cancer (mCRC).
• Cardiff Oncology reported a net loss attributable to common stockholders of approximately $41.5 million for 2023, compared to $38.7 million in 2022.
• As of December 31, 2023, the company had approximately $74.8 million in cash, cash equivalents, and short-term investments.
• The company's research and development expenses increased to $32.9 million in 2023 from $27.1 million in 2022, primarily due to clinical program costs.
• The company is advancing onvansertib through multiple clinical trials, including a Phase 2 trial in first-line RAS-mutated mCRC (CRDF-004) and investigator-initiated trials in mPDAC, SCLC, and TNBC.
• Interim data from the CRDF-004 trial is expected in mid-2024.
• The company discontinued enrollment in the ONSEMBLE trial (CRDF-003) to focus on the first-line mCRC program.
• Preliminary data from the CRDF-001 trial in mPDAC showed a 19% objective response rate and a 5.0-month median progression-free survival.
• The company is also exploring biomarkers to predict patient response to onvansertib.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as clinical trial progress and a strong cash position, the company's significant losses, reliance on external funding, and the discontinuation of a trial temper the overall outlook.

Positives

• The company has a strong cash position of $74.8 million to support ongoing clinical trials.
• The company is actively advancing onvansertib through multiple clinical trials across different cancer types.
• The company is using biomarker analysis to optimize drug development and patient care.
• The company has a collaborative relationship with Pfizer, which is responsible for the clinical activities of the CRDF-004 trial.
• The company has a robust intellectual property portfolio with 53 issued patents and 43 pending patent applications.

Negatives

• The company reported a net loss of $41.5 million for 2023.
• The company has incurred losses since its formation and has an accumulated deficit of approximately $339.5 million.
• The company discontinued enrollment in the ONSEMBLE trial, which may raise concerns about the second-line mCRC program.
• The company is dependent on third-party manufacturers for its product candidate.
• The company is subject to significant risks and uncertainties inherent in the development of a pharmaceutical product candidate.

Risks

• The company will need to raise substantial additional capital to develop and commercialize onvansertib.
• The company's product candidate is in the early stages of clinical development and its commercial viability remains subject to current and future preclinical studies, clinical trials, and regulatory approvals.
• Unfavorable or delayed results from preclinical studies or clinical trials could delay or preclude further development or commercialization of the product candidate.
• The company relies on third-party vendors for preclinical studies and clinical trials, and their failure to perform could delay or terminate these studies.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and unpredictable.
• The company has limited experience in the development of therapeutic product candidates.
• The company's product candidate may not gain acceptance among physicians, patients, and the medical community.
• The company's common stock price may be volatile and could fluctuate widely in price.

Future Outlook

The company plans to initiate CRDF-005, a Phase 3 trial, contingent upon the results of CRDF-004. The company expects that its capital resources are sufficient to fund operations into the third quarter of 2025.

Management Comments

• Management believes that the company has sufficient cash to meet its funding requirements for at least the next 12 months.
• Management is focused on advancing onvansertib through multiple clinical trials.

Industry Context

The company operates in the competitive biotechnology industry, facing challenges from established pharmaceutical companies and other research institutions. The company is focused on developing novel therapies for cancers with high unmet medical needs, such as RAS-mutated mCRC, mPDAC, SCLC, and TNBC.

Comparison to Industry Standards

• The reported ORR of 29% in the TROV-054 trial for KRAS-mutated mCRC is higher than historical controls of 5-13% for similar patient populations.
• The mPFS of 9.3 months in the TROV-054 trial is also longer than historical controls of 4.5-6.7 months.
• The 19% ORR and 5.0-month mPFS in the CRDF-001 trial for mPDAC are also higher than historical controls of 7.7% and 3.1 months, respectively.
• These results suggest that onvansertib may offer a potential improvement over existing treatments in these cancer types.
• The company's approach of combining onvansertib with standard-of-care therapies is consistent with current trends in oncology drug development.

Management Changes

Corporate Governance

Legal Proceedings

• The company states that there are no claims against it that are believed to result in a material adverse effect on its business or financial condition.

Stakeholder Impact

• Shareholders are exposed to risks associated with the company's financial losses and the uncertainty of clinical trial outcomes.
• Employees are subject to the company's clawback policy, which may affect their compensation.
• Patients may benefit from the development of new cancer therapies, but also face the risks associated with clinical trials.
• Suppliers and creditors are subject to the company's financial stability and ability to meet its obligations.

Next Steps

• The company anticipates interim data from the CRDF-004 trial in mid-2024.
• The company plans to initiate CRDF-005, a Phase 3 trial, contingent upon the results of CRDF-004.
• The company will continue to advance its other clinical programs in mPDAC, SCLC, and TNBC.

Key Dates

Keywords

onvansertib, PLK1 inhibitor, metastatic colorectal cancer, mCRC, pancreatic cancer, mPDAC, small cell lung cancer, SCLC, triple negative breast cancer, TNBC, clinical trials, biomarkers, cancer therapy, drug development, FDA approval